Evidence map›Paper›PMID 31569515›Full record

ArticlePharmaceutics2019

Formulation Composition and Process Affect Counterion for CSP7 Peptide.

Sawittree Sahakijpijarn, Chaeho Moon, John J Koleng, Robert O Williams

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sawittree SahakijpijarnCollege of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, TX 78712, USA. sawittree.willy@utexas.edu.ORCID 0000-0002-5828-1250
Chaeho MoonCollege of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, TX 78712, USA. chaehomoon@utexas.edu.ORCID 0000-0001-6986-5158
John J KolengAffiliation Lung Therapeutics, Inc., 2801 Via Fortuna Way, Austin, TX 78746, USA. jkoleng@alphavektor.com.ORCID 0000-0002-5881-8169
Robert O WilliamsCollege of Pharmacy, The University of Texas at Austin, 2409 University Ave, Austin, TX 78712, USA. bill.williams@austin.utexas.edu.ORCID 0000-0003-4993-6427
The University of Texas at Austin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect counterion volatilization. The development of lyophilized formulations containing volatile compounds is a challenge because these compounds sublimate away during the process. This work aims to investigate the effect of excipients and lyophilization parameters on the preservation of volatile compounds after lyophilization. The peak areas obtained from

Indexed as

bulking agentcounterioncounterion volatilizationlyophilizationpeptide aggregationvolatile compounds

Identifiers

PMID31569515
PMCPMC6835953
OpenAlexW2976910813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.